
Boston Scientific set to buy Penumbra for $14.5B, expanding vascular devices portfolio
Boston Scientific plans to acquire Penumbra for about $14.5 billion in cash and stock, gaining Penumbra’s thrombectomy and embolization devices to broaden its vascular portfolio. The deal values Penumbra at $374 per share and is expected to close in 2026 pending shareholder and regulatory approvals, with Penumbra generating about $1.4 billion in revenue for 2025. Analysts say the price is fair and the acquisition aligns with a trend of medtech consolidation.










